NEWS
Hatchtech has in recent times:

• made strong progress in the identification, design and development
of novel insect ovicides and larvicides for a range of pests and applications

• identified the key mechanisms involved in insect egg hatch

• patented a new class of novel invertebrate pest control compounds with novel targets and mode of action

• demonstrated strong proof of principle
in a range of important crop, horticultural, veterinary and industrial insect pests

• ongoing discussions with and strong interest in its programmes from market leaders in various pest and parasite control sectors

• successfully raised funds through two VC funding rounds

• secured $2.85 million in Grants from the Australian Federal Government

• completed pre-clinical safety testing of its lead human head lice control product, DeOvo

• completed a Phase I clinical trial of its lead human head lice control product, demonstrating a high level of safety

• through exploitation of knowledge regarding target and mode of action, expanded its activities outside insect eggs to include control of insect, mite and nematode eggs and larvae

• Submitted and had accepted by the US FDA an IND filing for DeOvo Phase II programme

MEDIA

June 2006: How lice are becoming invincible

They are the unwanted visitors that every mother dreads. As a nation, we [the UK] spend £30 million every year on lotions and potions to rid our children of head lice. But the little critters must be mocking our efforts for they have defeated most of what the chemist can throw at them.

READ MORE

PRESS RELEASES
January 2008: Hatchtech headlice treatment to go to Phase II trial after US FDA green light to IND

"The US Food and Drug Administration (FDA) has accepted Hatchtech’s Investigational New Drug (IND) application allowing immediate commencement of Phase II clinical trials of the new ovicidal head lice treatment DeOvo™. These are multi-centre international trials and come after Hatchtech successfully completed DeOvo™ Phase I studies in Australia in 2007."

READ MORE

December 2007: Hatchtech appoints Stewart Washer chairman

"Anti-egg hatching technology company Hatchtech Pty Ltd has appointed Dr Stewart Washer as chairman of its board of directors. Dr Washer is best known for his past 15 years commercialising biotechnology and agribusiness technologies in Australia and New Zealand."

May 2007: DeOvo™ anti-louse product successfully completes Phase I
safety study in human volunteers

"Hatchtech’s head louse control product has completed its first human trials finding no side effects or other adverse events associated with the product. 32 patients were treated at escalating dose levels and carefully monitored via observation, blood tests and electrocardiography. The trial was conducted by Q-Pharm in Queensland from February to April 2007."

January 2007: New Commercial Ready Grant to develop crop protection products using egg hatch inhibition technology

"Egg hatch control company Hatchtech Pty Ltd will commence development of a novel crop pest control product using a newly awarded $225,000 AusIndustry Commercial Ready Grant. The 12-month proof of concept project will commence this month to confirm product efficacy, mammalian safety and plant safety. "

READ MORE

September 2006: Hatchtech appoints Terry Bunn as new Director

"As Hatchtech’s core strength is a strong, sustainable pest control technology with
a growing focus on crop protection products, Mr Bunn’s substantial experience and expertise in this sector
will be invaluable in moving the Company forward and onto a commercial footing."
READ MORE

June 2006: Hatchtech wins major commercialisation prizes

"Melbourne based biotechnology company Hatchtech Pty Ltd was on Monday night honoured by winning two important prizes for commercialisation of technology that has enabled it to develop its world-leading lice control product."
READ MORE

May 2006: Hatchtech qualifies human head lice lead

"Melbourne based biotechnology company Hatchtech Pty Ltd will proceed with full development of a lead head lice control candidate. The company will appoint a European laboratory to commence
the pre-clinical and toxicity testing in readiness for the first human trials later this year."
READ MORE